Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 5/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759096 | 0.97 | — | — | |
| SCHEMBL26115972 | 0.83 | MEN1 (0.47) | MEN1KMT2AAPPTSHRMAPK1 | |
| SCHEMBL11897586 | 0.83 | MEN1 (0.47) | MEN1KMT2AAPPTSHRMAPK1 | |
| SCHEMBL26110338 | 0.83 | MEN1 (0.47) | MEN1KMT2AAPPTSHRMAPK1 | |
| SCHEMBL26110667 | 0.83 | MEN1 (0.47) | MEN1KMT2AAPPTSHRMAPK1 | |
| SCHEMBL26111792 | 0.83 | MEN1 (0.47) | MEN1KMT2AAPPTSHRMAPK1 | |
| SCHEMBL5583703 | 0.83 | MEN1 (0.38) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL6339770 | 0.83 | MEN1 (0.38) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL3306407 | 0.79 | — | — | |
| SCHEMBL1758971 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701637-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-9452985-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20160271278-A1 | TAU IMAGING PROBE | GE HEALTHCARE LTD (GB) | 2016-09-22 | — | — | US | disclosed |
| EP-2634177-B1 | TAU IMAGING PROBE | CLINO LTD (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-9249101-B2 | Tau imaging probe | CLINO LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20160008494-A1 | TAU IMAGING PROBE | GE HEALTHCARE LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-20130324523-A1 | TAU IMAGING PROBE | CLINO LTD. (JP) | 2013-12-05 | — | — | US | disclosed |
| EP-2634177-A1 | TAU IMAGING PROBE | Clino Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8383862-B2 | Salt compound, cationic polymerization initiator and cationically polymerizable composition | ADEKA CORPORATION (JP) | 2013-02-26 | — | — | US | disclosed |
| EP-2223948-B1 | SALT COMPOUND, CATIONIC POLYMERIZATION INITIATOR AND CATIONICALLY POLYMERIZABLE COMPOSITION | ADEKA CORP (JP) | 2013-01-23 | — | — | EP | disclosed |
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | NAGASAKI UNIVERSITY (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100267857-A1 | SALT COMPOUND, CATIONIC POLYMERIZATION INITIATOR AND CATIONICALLY POLYMERIZABLE COMPOSITION | ADEKA CORPORATION (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2223948-A1 | SALT COMPOUND, CATIONIC POLYMERIZATION INITIATOR AND CATIONICALLY POLYMERIZABLE COMPOSITION | Adeka Corporation (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20100003191-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | NAGASAKI UNIVERSITY (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2113258-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | Nagasaki University (JP) | 2009-11-04 | — | — | EP | disclosed |
| EP-2030635-A1 | COMPOSITION FOR DIAGNOSING AMYLOID-RELATED DISEASE | Nagasaki University (JP) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267857-A1 | SALT COMPOUND, CATIONIC POLYMERIZATION INITIATOR AND CATIONICALLY POLYMERIZABLE COMPOSITION | RFC5, RER1, ARF5 | MEN1 2796/4885KMT2A 3677/4885APP 4348/4885 |
| US-20160008494-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | MEN1 442/4885KMT2A 4570/4885APP 2/4885 |
| US-20130324523-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | MEN1 442/4885KMT2A 4570/4885APP 2/4885 |
| US-20160271278-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | MEN1 442/4885KMT2A 4570/4885APP 2/4885 |
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | APP, FABP7, APBA1 | MEN1 2789/4885KMT2A 4612/4885APP 1/4885 |
| US-20100003191-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | APP, APBA1, BACE1 | MEN1 508/4885KMT2A 3747/4885APP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.